rhAAT

rhAAT refers to recombinant human alpha-1 antitrypsin. Alpha-1 antitrypsin is a protein naturally produced in the body, primarily in the liver, that plays a crucial role in protecting the lungs from damage caused by certain enzymes, particularly neutrophil elastase. Genetic deficiencies in alpha-1 antitrypsin can lead to a higher risk of developing lung diseases like emphysema and liver disease.

Recombinant technology allows for the production of human alpha-1 antitrypsin in laboratory settings, often using genetically modified organisms such as bacteria, yeast, or cell cultures. This recombinant form, rhAAT, is identical or very similar in structure and function to the alpha-1 antitrypsin produced by the human body.

The primary therapeutic use of rhAAT is in the treatment of individuals with alpha-1 antitrypsin deficiency. By administering rhAAT, physicians aim to supplement the deficient levels of the protein in patients, thereby helping to reduce the progressive damage to the lungs. This treatment is typically administered intravenously. Research has also explored potential applications of rhAAT in other inflammatory conditions where alpha-1 antitrypsin's protective properties might be beneficial, though these are generally considered investigational.